Soleus Capital Management’s BioNTech BNTX Stock Holding History

Soleus Capital Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-98,000	Closed	-$10.6M	–	82
2023 Q3	$10.6M	Buy	+98,000	New	+$10.8M	0.98%	34

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AGA

Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return

Soleus Capital Management's BNTX Position: Q4 2023 in Review

Soleus Capital Management sold out of BioNTech (BNTX) in Q4 2023, closing a stake of 98,000 shares — an estimated $10.6M sold.

Soleus Capital Management first reported a position in BNTX in Q3 2023 and held it in 1 quarter. The position peaked at $10.6M in Q3 2023. 282 funds tracked by Wall St. Rank hold BNTX as of Q4 2023.

Soleus Capital Management reported no remaining BioNTech position as of Q4 2023 after selling out during the quarter.
Soleus Capital Management sold 98,000 BioNTech shares in Q4 2023, an estimated $10.6M.
Soleus Capital Management first reported a position in BioNTech in Q3 2023 and held it in 1 quarter.
Soleus Capital Management's BioNTech position peaked at $10.6M in Q3 2023.
282 funds tracked by Wall St. Rank held BioNTech as of Q4 2023.

Based on Soleus Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.